Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNAGlobeNewsWire • 05/14/21
Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 05/06/21
New Preclinical Data from Dyne Therapeutics' Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual MeetingGlobeNewsWire • 04/27/21
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent HighlightsGlobeNewsWire • 03/04/21
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical OfficerGlobeNewsWire • 03/04/21
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical AffairsGlobeNewsWire • 02/08/21
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical StudyGlobeNewsWire • 01/10/21
